Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is -4.95% lower on its value in year-to-date trading and has touched a low of $5.38 and a high of $16.20 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ARQT stock was last observed hovering at around $13.67 in the last trading session, with the day’s loss setting it -0.43%.
Currently trading at $13.24, the stock is -5.10% and 0.33% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.66 million and changing -3.15% at the moment leaves the stock 28.47% off its SMA200. ARQT registered 125.55% gain for a year compared to 6-month gain of 31.48%. The firm has a 50-day simple moving average (SMA 50) of $13.1969 and a 200-day simple moving average (SMA200) of $10.306075.
The stock witnessed a -6.76% loss in the last 1 month and extending the period to 3 months gives it a 54.67%, and is -4.40% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.90% over the week and 7.04% over the month.
Arcutis Biotherapeutics Inc (ARQT) has around 296 employees, a market worth around $1.55B and $138.71M in sales. Profit margin for the company is -140.97%. Distance from 52-week low is 146.10% and -18.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-73.92%).
The EPS is expected to grow by 65.01% this year.
Arcutis Biotherapeutics Inc (ARQT) Top Institutional Holders
264.0 institutions hold shares in Arcutis Biotherapeutics Inc (ARQT), with institutional investors hold 116.68% of the company’s shares. The shares outstanding are 117.00M, and float is at 102.98M with Short Float at 19.63%. Institutions hold 114.42% of the Float.
The top institutional shareholder in the company is JENNISON ASSOCIATES LLC with over 11.57 million shares valued at $107.62 million. The investor’s holdings represent 9.3712% of the ARQT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 10.0 million shares valued at $93.04 million to account for 8.1021 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 9.82 million shares representing 7.95% and valued at over $91.3 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 7.1147 of the shares totaling 8.79 million with a market value of $81.7 million.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
The most recent transaction is an insider sale by Welgus Howard G., the company’s Director. SEC filings show that Welgus Howard G. sold 10,000 shares of the company’s common stock on Jan 02 ’25 at a price of $14.67 per share for a total of $0.15 million. Following the sale, the insider now owns 0.15 million shares.
Still, SEC filings show that on Dec 31 ’24, Burnett Patrick disposed off 1,691 shares at an average price of $14.00 for $23674.0. The insider now directly holds 126,978 shares of Arcutis Biotherapeutics Inc (ARQT).
